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INTRODUCTION
Statin treatment has persistently demonstrated a significant 
benefit in diminishing cardiovascular disease (CVD) risk, espe-
cially in primary prevention settings.1,2 Recently, the American 
College of Cardiology (ACC) and American Heart Association 
(AHA) reported extensively on cholesterol management guide-
lines, focusing on the use of statin therapy for prevention of 
CVD, based on a new pooled cohort risk equation designed to 
predict 10-year risk of atherosclerotic cardiovascular disease 
(ASCVD).3 Although these updated guidelines increased the el-
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Purpose: The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol management guide-
lines advocate the use of statin treatment for prevention of cardiovascular disease. We aimed to assess the usefulness of coronary 
artery calcium (CAC) for stratifying potential candidates of statin use among asymptomatic Korean individuals.
Materials and Methods: A total of 31375 subjects who underwent CAC scoring as part of a general health examination were en-
rolled in the current study. Statin eligibility was categorized as statin recommended (SR), considered (SC), and not recommend-
ed (SN) according to ACC/AHA guidelines. Cox regression analysis was employed to estimate hazard ratios (HR) with 95% confi-
dential intervals (CI) after stratifying the subjects according to CAC scores of 0, 1–100, and >100. Number needed to treat (NNT) 
to prevent one mortality event during study follow up was calculated for each group.
Results: Mean age was 54.4±7.5 years, and 76.3% were male. During a 5-year median follow-up (interquartile range; 3–7), there 
were 251 (0.8%) deaths from all-causes. A CAC >100 was independently associated with mortality across each statin group after 
adjusting for cardiac risk factors (e.g., SR: HR, 1.60; 95% CI, 1.07–2.38; SC: HR, 2.98; 95% CI, 1.09–8.13, and SN: HR, 3.14; 95% CI, 
1.08–9.17). Notably, patients with CAC >100 displayed a lower NNT in comparison to the absence of CAC or CAC 1–100 in SC and 
SN groups.
Conclusion: In Korean asymptomatic individuals, CAC scoring might prove useful for reclassifying patient eligibility for receiving 
statin therapy based on updated 2013 ACC/AHA guidelines.
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igibility of patients for statin treatment, they also led to an over-
estimation of CVD risk in several particularistic populations.4-6
Coronary artery calcium (CAC) score is determined using 
cardiac computed tomography and acts a robust marker of cor-
onary artery calcification. Prior studies have reported that CAC 
score is closely associated with increased coronary atheroscle-
rotic burden, as well as future onset of adverse cardiac events.7-10 
Current guidelines for assessing CVD recommend that CAC 
screening should be considered for primary risk assessment in 
asymptomatic populations.11 Furthermore, more recent studies 
have documented that reclassification of populations accord-
ing to CAC score may facilitate treatment decision-making in 
clinical settings.12-14
Cardiovascular disease burden tends to differ according to 
ethnicity. Indeed, Asians often present with a low risk for 
CVD.15,16 Accordingly, assessing the efficacy of statin treatment 
according to the recently updated 2013 ACC/AHA guidelines in 
these individuals is warranted. Using a large multicenter regis-
try of asymptomatic Korean adults, we sought to explore 
whether CAC scoring could reclassify individuals recommend-
ed for statin treatment according to the recently updated 2013 
ACC/AHA cholesterol management guidelines.
MATERIALS AND METHODS
Study design and population
This study population belonged to the KOrea Initiative on Coro-
nary Artery calcification (KOICA) registry. The KOICA registry 
is a single ethnicity, multicenter, observational registry of self-
referred individuals who underwent a health check-up at one 
of three healthcare centers in South Korea (i.e., Severance Check-
up Healthcare Center; Seoul National University Healthcare 
System, Gangnam Center; and Samsung Medical Center in 
Seoul, South Korea). A total of 48903 individuals were recruited 
between December 2002 and July 2014. For the purposes of this 
study, subjects were deemed eligible for study inclusion if they 
were of an age between 40 to 75 years and had no known CVD 
at baseline. Otherwise, individuals were excluded from the 
study if they were prescribed any lipid-lowering medication or 
were missing any values related to risk factors used for calculat-
ing 10-year ASCVD risk or CAC score. Hence, after applying the 
inclusion and exclusion criteria, 31375 individuals were subse-
quently enrolled in the current analysis (Fig. 1). The appropriate 
institutional review board committees at all centers approved 
the study protocol.
Acquisition of clinical factors
Baseline demographic and risk factors were collected at the 
time of each initial visit to the healthcare centers. Age, gender, 
body mass index, and systolic and diastolic blood pressure 
were measured as baseline demographic profiles. A self-report-
ed medical questionnaire was used to obtain information on 
past medical history. Presence of hypertension was defined as 
a history of being diagnosed with hypertension or taking anti-
hypertensive medications. Presence of diabetes mellitus was 
defined as a history of being diagnosed with diabetes or receiv-
ing medication for diabetes. Current smoking was defined as 
active smoking status. Total, high-density lipoprotein, and low-
density lipoprotein (LDL) cholesterol were obtained after par-
ticipants had fasted for a minimum 8 h. CACS was measured 
using a >16-slice CT scanner. Specific CT scanner types used 
within each center included the Philips Brilliance 256 iCT, Phil-
ips Brilliance 40 channel multi-detector CT (Philips Healthcare, 
Cleveland, OH, USA), Siemens 16-slice Sensation (Siemens AG, 
Forchheim, Germany), and GE 64-slice Lightspeed (GE Health-
care, Milwaukee, WI, USA). A calcium scan was performed us-
ing standard prospective or retrospective methods with a 225 to 
400 ms gantry rotation time. Image data were reconstructed 
with a 2.5- to 3-mm slice thickness. Calcium score analysis was 
performed using dedicated workstations (AW Volume Share 5 
workstation, GE Healthcare; Rapidia 3D, Infinitt Co., Seoul, Ko-
rea; EBW workspace version 3.5, Philips Healthcare) and analy-
sis software (Smart Score 4.0, GE Healthcare; Rapidia3D, Infinitt 
Co.; HeartBeat CS, Philips Healthcare). Estimated radiation 
doses for CACS ranged between 0.7–1.5 mSv. CAC score was 
calculated based on the Agatston scoring method,17 and sub-
jects were categorized according to the presence any of CAC 
(CAC>0), as well as CAC 0, 1–100, and >100 based on the back-
ground of CAC.18,19
Statin candidate groups
In this study population, we calculated 10-year ASCVD risk, 
based on that for Caucasians, and subsequently categorized 
participants according to 2013 ACC/AHA cholesterol manage-
ment guidelines using the following groups: statin recom-
mended (SR), statin considered (SC), and statin not recom-
Fig. 1. Study flow chart of participant groups. KOICA, KOrea Initiative on 
Coronary Artery calcification; CAD, coronary artery disease; ASCVD, ath-
erosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cho-
lesterol; CAC, coronary artery calcium.
Age <40 years, >75 years: 
n=2603
48901 KOICA population
Statin considered
n=4046
Statin not recommended
n=13441
LDL-C <70 mg/dL: n=1198
Prior history of stroke: n=237
Known CAD: n=1953
Taking lipid medication: n=1953
Missing risk factors for ASCVD: 
n=9646
Missing CAC: n=287
Statin recommended
n=13888
31375 study population
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mended (SN) (Table 1).3 Specifically, the SR group was defined 
as either: 1) those with LDL cholesterol levels ≥190 mg/dL, 2) 
those aged 40 to 75 years with diabetes and LDL cholesterol 
levels ranging from 70 to 189 mg/dL, or 3) individuals without 
diabetes, but with an estimated 10-year ASCVD risk of 7.5% or 
higher. The SC and SN groups were defined as individuals with-
out diabetes or ASCVD events and with a 10-year ASCVD risk 
of between 5% to 7.5%, and <5%, respectively.
Study outcome
The primary outcome of the KOICA registry is all-cause mortal-
ity (ACM). Ascertainment of ACM events was determined by 
querying the Ministry of Security and Public Administration up 
until December 2014 for two centers and until September 2014 
in the remaining center.
Statistical methods
Continuous variables are reported as means with standard de-
viations, and categorical variables are reported as counts with 
proportions. A one-way analysis of variance (ANOVA) was used 
for the comparison of continuous variables across statin groups, 
and Pearson’s Chi-squared test was employed for comparison 
of categorical variables between statin groups. Cumulative 
mortality events over time according to CAC categories and 
statin candidate groups were calculated by use of the Kaplan-
Meier method and compared using the log rank test. Time to 
mortality event was assessed using incidence rates per 1000 
person years. Further, Cox regression analysis was used to esti-
mate the risk of ACM according to CAC categories across statin 
candidate groups, reporting adjusted hazard ratios (HR) with 
95 % confidence intervals [95% confidential interval (CI)]. Mod-
els were adjusted for age, gender, BMI, hypertension, and cur-
rent smoking. We calculated number needed to treat (NNT) to 
prevent one mortality event by applying the mortality risk asso-
ciated with statin treatment in primary prevention on the basis 
of a Cochrane meta analysis.20 The results from 18 randomized 
control trials showed that the incidence of ACM is lowered by 
14% according to statin treatment (odds ratio: 0.86, 95% CI: 0.79 
to 0.94). The 5-year NNT was calculated as the reciprocal of the 
absolute risk difference at 5-year follow up based on Kaplan-
Meier estimates, according to the Altman and Andersen21 meth-
od, in each CAC category across statin candidate groups. A two-
tailed p value <0.05 was considered statistically significant. All 
statistical analyses were performed using STATA Version 13 
(StataCorp LP, College Station, TX, USA).
RESULTS
Baseline characteristics
Mean age of the study participants was 54.4±7.5 years, and 
23923 (76.3) were male. Baseline characteristics according to 
the statin candidate groups are shown in Table 2. Demographic 
variables and lipid profiles differed among the three statin can-
didate groups. CAC distribution according to statin eligibility is 
displayed in Fig. 2. The proportion of zero CAC was more than 
50% across all statin candidate groups, while the proportion of 
a CAC score >100 tended to increase within the SR group (16%), 
as compared with the SC (10%) and SN groups (4%), respec-
tively.
Table 1. Statin Eligibility in Study Population
Classification Number (%)
SR
LDL-C≥190 2883 (9.2)
DM with LDL 70–189 4797 (15.3)
ASCD risk≥7.5% 6208 (19.8)
SC
ASCVD risk 5–7.5% 4046 (12.9)
SN
ASCVD risk <5% 13441 (42.8)
SR, statin recommend; SC, statin considered; SN, statin not recommended; 
LDL-C, low-density lipoprotein cholesterol; DM, diabetes mellitus; ASCVD, 
atherosclerotic cardiovascular disease.
Table 2. Baseline Characteristics among Statin Candidate Groups
SR group (n=13888) SC group (n=4046) SN group (n=13441) p value
Age 58.2±7.7 55.0±5.5 50.2±5.2 <0.001
Male 11394 (82.0) 3457 (85.4) 9072 (67.5) <0.001
SBP 124.4±15.7 121.7±14.5 116.1±13.9 <0.001
DBP 78.9±10.8 78.9±10.3 74.9±10.7 <0.001
BMI 24.7±2.8 24.8±2.6 24.0±2.9 <0.001
Hypertension 7305 (52.8) 1735 (43.6) 4524 (33.9) <0.001
Current smoker 4718 (34.0) 1342 (33.2) 1662 (12.4) <0.001
TC 201.5±35.0 201.0±29.4 196.3±29.7 <0.001
HDL-C 50.6±12.0 50.6±129.7 55.1±13.0 <0.001
LDL-C 130.5±32.0 129.7±25.9 124.1±26.0 <0.001
SR, statin recommended; SC, statin considered; SN, statin not recommended; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; 
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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All-cause mortality and CAC across statin 
candidate groups
During a median follow-up of 5 years (25–75th percentile: 3–7 
years), 251 mortality events occurred among 31375 subjects. 
Fig. 3 shows the incidence of mortality per 1000 person-years 
for each CAC category by statin candidate group. Notably, mor-
tality events tended to be higher among subjects with a CAC 
score >100, compared with the other CAC groups. In Cox re-
gression analysis, a CAC score >100 was independently associ-
ated with ACM in all three statin candidate groups, even after 
adjusting for numerous cardiac risk factors (Table 3). In particu-
lar, in the SN group, the adjusted risk of death for those with a 
CAC score >100 increased by more than three-fold (HR, 3.14; 
95% CI, 1.08–9.17; p value, 0.036), compared with those in the 
SN group with a CAC=0.
Number needed to treatment
In Fig. 4, Kaplan-Meier survival curves revealed that increasing 
CAC score categories were associated with a concurrent rise in 
mortality across each of the statin candidate groups (Log rank p 
values were <0.01 in overall, SR, and SC groups, and p val-
ue=0.07 in SN group). Based on Kaplan-Meier estimates, the 
5-year NNTs to prevent one ACM event was 834, 1250, and 2000 
for CAC score 0; 500, 1250, and 1429 for CAC scores 1–100; and 
385, 667, and 500 for CAC scores more than 100 in the SR, SC, 
and SN groups, respectively (Table 4). Foremost, subjects with a 
CAC score >100 demonstrated the lowest NNT across all statin 
candidate groups.
DISCUSSION
In this multicenter observational study, we assessed the impact 
of CAC for reclassifying statin candidates according to the 2013 
ACC/AHA cholesterol management guidelines for primary 
prevention. The results of the present study showed that CAC is 
closely related to a greater risk of ACM. Specifically, a CAC 
score >100 independently increased the risk of ACM across all 
statin candidate groups, while the NNT for preventing one 
mortality event during the current study period was lower 
among subjects with a CAC score >100 in the SC and SN groups. 
The 2013 ACC/AHA guidelines for the assessment of cardiovas-
cular risk recommend that CAC screening should be consid-
ered only among cases in which treatment decisions remain 
uncertain following quantitative risk assessment.11 Neverthe-
less, the results of the current investigation indicated that CAC 
screening may be of use in guiding initiation of statin treatment 
in asymptomatic individuals.
In 2014, the ACC/AHA reported new cholesterol manage-
ment guidelines that were based on 10-year ASCVD risk.3 In 
comparison with previous scores, such as the Third Report of 
the National Cholesterol Education Program (NCEP ATP-III) 
guidelines,22 in this study, the statin-eligible population was sig-
nificantly increased when applying the new guidelines. Further 
still, Pencina, et al.6 reported that the more recent guidelines 
would increase the number of candidates for statin treatment 
by 11.1% or 12.8 million, especially in primary prevention set-
tings, using data from the United States National Health Survey. 
Although the use of statins could have a large public health 
benefit,23 statins cannot be recommended purely on the basis 
of high risk, given concerns for efficacy, potential side effects, 
and health-related costs.24,25 Therefore, the implication of the 
new cholesterol management guidelines should be carefully 
assessed.
In prior research, statin therapy exhibited different effects 
between Western and Asian populations. For example, the ini-
tiation of statin therapy in Asian populations usually begins 
Fig. 2. Distribution of coronary artery calcium scores according to statin 
candidate groups. CAC, coronary artery calcium.
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Fig. 3. Incident mortality (per 1000 person-years) according to coronary 
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Table 3. Risk of All-Cause Mortality by CAC Burden Across Statin Candidate Groups
Unadjusted Adjusted*
Event HR 95% CI p value HR 95% CI p value
SR group
CAC=0 68 Ref Ref
CAC=1–100 63 1.62 1.15–2.29 0.006 1.14 0.80–1.63 0.461
CAC>100 47 2.82 1.94–4.10 <0.001 1.60 1.07–2.38 0.022
Any CAC 110 1.98 1.46–2.68 <0.001 1.29 0.93–1.77 0.124
SC group
CAC=0 13 Ref Ref
CAC=1–100 6 0.92 0.35–2.41 0.860 0.76 0.28–2.02 0.579
CAC>100 6 3.66 1.38–9.71 0.009 2.98 1.09–8.13 0.033
Any CAC 12 1.46 0.67–3.21 0.342 1.19 0.53–2.66 0.667
SN group
CAC=0 36 Ref Ref
CAC=1–100 8 0.96 0.45–2.07 0.920 0.93 0.43–2.06 0.867
CAC>100 4 3.13 1.11–8.84 0.031 3.14 1.08–9.17 0.036
Any CAC 12 1.25 0.65–2.40 0.505 1.21 0.61–2.39 0.584
CAC, coronary artery calcium; SR, statin recommended; SC, statin considered; SN, statin not recommended; HR, hazard ratio; CI, confidential interval.
*Adjusted by age, gender, body mass index, study site, hypertension, current smoking.
Fig. 4. Kaplan-Meier survival curves according to coronary artery calcium scores and statin candidate groups. CAC, coronary artery calcium.
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with a lower dose, compared to Western populations, as the 
pharmacokinetics and metabolites of statins differ substantially 
by ethnicity.26 Moreover, the Management of Elevated Choles-
terol in the Primary Prevention Group of Adult Japanese (MEGA) 
study reported that the low dosage statin prescribed therein 
was half the dose often utilized in European and U.S. popula-
tions and could significantly lower the risk of coronary heart 
disease in Japanese patients.27 A recent meta-analysis evaluat-
ing the effect of statin therapy on coronary plaque also docu-
mented a different effect of statins for modifying LDL-choles-
terol levels, as well as the regression of coronary atherosclerotic 
plaque, among ethnic groups.28
In this study, we employed CAC as a marker for reclassifica-
tion of statin treatment. It is well known that CAC score has 
added benefit towards cardiovascular risk prediction over con-
ventional risk tools.29,30 An additional strength is that CAC can 
be employed to better define target populations who require 
preventive treatment through prescribing cardiovascular medi-
cations. Indeed, Miedema, et al.13 investigated aspirin use for 
primary prevention of CHD in the Multi-Ethnic Study of Ath-
erosclerosis (MESA). In that study, participants with a CAC 
score >100 showed favorable risk/benefit estimation on the 
background of aspirin use. Similarly, Blaha, et al.12 showed that 
CAC might have benefit for defining rosuvastatin eligible par-
ticipants according to the Justification for the Use of Statins in 
Prevention: an Intervention Trial Evaluating Rosuvastatin (JU-
PITER) trial.31 The results of the latter study demonstrated that 
the absence of CAC was related to an extremely lower CVD 
event rate in statin eligible participants.
Recently, Nasir, et al.18 reported the implications of CAC test-
ing among statin candidates according to 2013 ACC/AHA cho-
lesterol management guidelines in the MESA population. In 
that study, ASCVD risk appeared to be heterogeneous among 
statin candidate groups, while CAC appeared to reclassify this 
population. To this end, the absence of CAC reclassified half of 
the candidates as not suitable for statin treatment. Our data 
supports those results in that CAC scoring also appeared to be 
effective in determining a target population among Asians who 
might benefit from statin therapy. Nevertheless, some disparity 
exists between these studies: Our study showed that a CAC 
>100 is closely associated with mortality events and can per-
haps identify participants who may be eligible for statin treat-
ment. However, the absence of CAC did not prove useful for 
predicting incident mortality or NNT when compared with the 
presence of CAC in our study population. It bears mentioning 
however, that the clinical outcomes differed between both 
studies, whereby ASCVD events included both ACM and non-
fatal CVD events in the MESA population while in the present 
study, only ACM events were included. In addition, the burden 
of CVD is lower in Korean populations than Western popula-
tions (i.e., MESA participants) that consist mainly of Cauca-
sians.15,32 Thus, the onset of adverse clinical events may only oc-
cur on the background of a higher level of CAC in Korean 
populations, particularly when compared with previous study 
cohorts, such as MESA.
Although, in this study, CAC scanning displayed some added 
benefit for reclassifying patient eligibility to receive statin thera-
py, the latter purpose of CAC scanning and its subsequent ben-
efits are somewhat offset in light of the anticipated rise in 
healthcare costs, as well as the burden of additional radiation 
exposure. Though, a recent investigation from MESA study 
showed that CAC screening is likely to incur cost savings, com-
pared with guideline based risk assessment strategies.33 More-
over, the radiation dose administered for CAC screening is con-
tinuously decreasing, with an effective median radiation dose 
comparable to mammograms.34
Limitations
The KOICA registry was designed retrospectively and observa-
tionally in nature. Thus, The KOICA population comprised only 
a self-referred population, and was predominantly male. 
Hence, our findings should be interpreted with caution when 
extrapolated to other populations. In light of the retrospective 
nature of this study and given treatment strategies for athero-
sclerotic disease have likely evolved since initial enrollment in 
2002 through 2014, persons enrolled later into the study might 
have received different treatment strategies, compared to those 
enrolled earlier, which could have offset the risk of the study 
outcome. While we selected individuals who did not receive 
any lipid-lowering medications at baseline, we were unable to 
assess medication use that may have been initiated during the 
study follow-up period. Hence, another limitation of this study 
was not being able to ascertain the prevalence of statin therapy 
beyond CAC examination. While the new cholesterol manage-
Table 4. NNT According CAC Categories Across Statin Candidate Group
Number NNT for ACM (14% RR*)
SR group
CAC=0 7092 834
CAC=1–100 4518 500
CAC>100 2278 385
Any CAC 6796 455
SC group
CAC=0 2422 1250
CAC=1–100 1227 1250
CAC>100 397 667
Any CAC 1624 1000
SN group
CAC=0 10454 2000
CAC=1–100 2494 1429
CAC>100 493 500
Any CAC 2948 1112
NNT, number needed to treat; CAC, coronary artery calcium; ACM, all-cause 
mortality; SR, statin recommended; SC, statin considered; SN, statin not rec-
ommended; RR, risk reduction.
*Based on a 14% relative reduction of ACM from a Cochran meta analysis.20
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ment guidelines were based on a 10-year risk of ASCVD, infor-
mation regarding ASCVD events was unavailable, as only ACM 
were ascertained in the KOICA registry. Therefore, further stud-
ies are needed to assess CAC and statin eligibility according to 
ASCVD events. Despite this, ACM is considered a useful clinical 
outcome as it lowers the potential for bias as opposed to utiliz-
ing a cause specific endpoint, particularly in a retrospectively 
designed study.35 Also, when estimating NNT, it is perhaps fea-
sible to consider the likelihood for some uncertainty with re-
gards to the application of reduction in risk of ACM on the 
background of Cochran’s meta-analysis. As such, our study’s 
NNT findings should be considered hypothesis generating only 
and interpreted with caution.
Conclusion
In a large sample of asymptomatic Koreans, CAC scoring fur-
ther reclassified individuals for eligibility of statin treatment ac-
cording to the recently updated 2013 ACC/AHA cholesterol 
management guidelines. Assessment of CAC scoring may prove 
useful for guiding treatment decision-making for initiating 
statins among Korean adults in a primary prevention setting.
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